Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Background: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. Objective: To report 4-year end-of-study bimekizumab effica...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2025 |
| Country: | España |
| Institution: | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| Repository: | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| OAI Identifier: | oai:iibsantpau.fundanetsuite.com:p20532 |
| Online Access: | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20532 |
| Access Level: | Open access |
| Keyword: | bimekizumab efficacy long-term plaque psoriasis psoriasis quality of life safety |
| _version_ | 1878741793648934912 |
|---|---|
| author | Blauvelt, A |
| author2 | Langley, RG Lebwohl, M Strober, B Warren, RB Puig, L Morita, A Gordon, KB Fernandez-Peña, P Kavanagh, S Pinto, JML Lambert, J Hoepken, B Deherder, D Cross, N Thaçi, D |
| author2_role | author author author author author author author author author author author author author author author |
| author_browse | Blauvelt, A Cross, N Deherder, D Fernandez-Peña, P Gordon, KB Hoepken, B Kavanagh, S Lambert, J Langley, RG Lebwohl, M Morita, A Pinto, JML Puig, L Strober, B Thaçi, D Warren, RB |
| author_facet | Blauvelt, A Langley, RG Lebwohl, M Strober, B Warren, RB Puig, L Morita, A Gordon, KB Fernandez-Peña, P Kavanagh, S Pinto, JML Lambert, J Hoepken, B Deherder, D Cross, N Thaçi, D |
| author_role | author |
| collection | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| description | Background: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. Objective: To report 4-year end-of-study bimekizumab efficacy and safety in patients with moderate to severe psoriasis. Methods: Data were pooled from 3 phase 3 trials (BE VIVID, BE READY, and BE SURE) and their open-label extension (OLE; BE BRIGHT). Efficacy is reported for patients who received bimekizumab continuously from baseline into the OLE. Safety is reported for patients who received $1 bimekizumab dose. Results: Seven hundred seventy-one patients received bimekizumab from baseline into the OLE. A high proportion achieved complete skin clearance (100% improvement from baseline in Psoriasis Area and Severity Index) at Week 52 (76.2%) and maintained this to Week 196 (64. 7%). The rate of treatment-emergent adverse events over 4 years was 169.8/100 patient-years (N = 1495) and did not increase with longer exposure. The most common treatment-emergent adverse events were nasopharyngitis, oral candidiasis, and upper respiratory tract infection, consistent with bimekizumab's known safety profile. Limitations: Eligibility criteria and ethnic representation. Conclusion: Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and durable long-term treatment option. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_eb738fea6bfdfec905e2fbcf0fc58e8c |
| institution | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| instname_str | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:iibsantpau.fundanetsuite.com:p20532 |
| publishDate | 2025 |
| publishDateSort | 2025 |
| publisher | MOSBY-ELSEVIER |
| publisherStr | MOSBY-ELSEVIER |
| reponame_str | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| spelling | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial Blauvelt, A Langley, RG Lebwohl, M Strober, B Warren, RB Puig, L Morita, A Gordon, KB Fernandez-Peña, P Kavanagh, S Pinto, JML Lambert, J Hoepken, B Deherder, D Cross, N Thaçi, D bimekizumab efficacy long-term plaque psoriasis psoriasis quality of life safety Background: Patients with moderate to severe psoriasis experience significant burden on quality of life. Long-term management with latest-generation biologics can facilitate sustained complete skin clearance and improved patient well-being. Objective: To report 4-year end-of-study bimekizumab efficacy and safety in patients with moderate to severe psoriasis. Methods: Data were pooled from 3 phase 3 trials (BE VIVID, BE READY, and BE SURE) and their open-label extension (OLE; BE BRIGHT). Efficacy is reported for patients who received bimekizumab continuously from baseline into the OLE. Safety is reported for patients who received $1 bimekizumab dose. Results: Seven hundred seventy-one patients received bimekizumab from baseline into the OLE. A high proportion achieved complete skin clearance (100% improvement from baseline in Psoriasis Area and Severity Index) at Week 52 (76.2%) and maintained this to Week 196 (64. 7%). The rate of treatment-emergent adverse events over 4 years was 169.8/100 patient-years (N = 1495) and did not increase with longer exposure. The most common treatment-emergent adverse events were nasopharyngitis, oral candidiasis, and upper respiratory tract infection, consistent with bimekizumab's known safety profile. Limitations: Eligibility criteria and ethnic representation. Conclusion: Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 4 years, making bimekizumab an effective, rapid, and durable long-term treatment option. MOSBY-ELSEVIER https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20532 |
| spellingShingle | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial Blauvelt, A bimekizumab efficacy long-term plaque psoriasis psoriasis quality of life safety |
| status_str | publishedVersion |
| title | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial |
| title_full | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial |
| title_fullStr | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial |
| title_full_unstemmed | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial |
| title_short | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial |
| title_sort | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial |
| topic | bimekizumab efficacy long-term plaque psoriasis psoriasis quality of life safety |
| topic_facet | bimekizumab efficacy long-term plaque psoriasis psoriasis quality of life safety |
| url | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20532 |